Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali

Trial Profile

Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Pfs25 Pfs230 malaria vaccine MVI (Primary) ; Hepatitis A-hepatitis B vaccine; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
    • 03 Dec 2015 Planned primary completion date changed from 1 May 2017 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
    • 03 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top